Dynamic Prediction of Survival after Curative Resection of Gastric Adenocarcinoma: A landmarking-based analysis

Author(s):  
Gaya Spolverato ◽  
Danila Azzolina ◽  
Alessandro Paro ◽  
Giulia Lorenzoni ◽  
Dario Gregori ◽  
...  
2019 ◽  
Vol 24 (10) ◽  
pp. 2212-2218
Author(s):  
Yinin Hu ◽  
Timothy L. McMurry ◽  
Bernadette Goudreau ◽  
Katie M. Leick ◽  
Tri M. Le ◽  
...  

Author(s):  
Behnaz ALAFCHI ◽  
Leili TAPAK ◽  
Omid HAMIDI ◽  
Jalal POOROLAJAL ◽  
Hossein MAHJUB

Background: Breast cancer is the first non-cutaneous malignancy in women and the second cause of death due to cancer all over the world. There are situations where researchers are interested in dynamic prediction of survival of patients where traditional models might fail to achieve this goal. We aimed to use a dynamic prediction model in analyzing survival of breast cancer patients. Methods: We used a data set originates from a retrospective cohort (registry-based) study conducted in 2014 in Tehran, Iran, information of 550 patients were available analyzed. A method of landmarking was utilized for dynamic prediction of survival of the patients. The criteria of time-dependent area under the curve and prediction error curve were used to evaluate the performance of the model. Results: An index of risk score (prognostic index) was calculated according to the available covariates based on Cox proportional hazards. Therefore, hazard of dying for a high-risk patient with breast cancer within the next five years was 2.69 to 3.04 times of that for a low-risk patient. The value of the dynamic C-index was 0.89 using prognostic index as covariate. Conclusion: Generally, the landmark model showed promising performance in predicting survival or probability of dying for breast cancer patients in this study in a predefined window. Therefore, this model can be used in other studies as a useful model for investigating the survival of breast cancer patients.


2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 150-150
Author(s):  
Paola Catherine Montenegro ◽  
Lourdes Lopez ◽  
Shirley Quintana ◽  
Luis Augusto Casanova ◽  
Victor Castro ◽  
...  

150 Background: Adjuvant chemoradiotherapy is the standard treatment in Western countries in gastric cancer patients submitted to curative resection. INT 0116 pivotal trial established adyuvant chemoradiation as the standar care for resected high risk adenocarcionoma of the stomach in US however was hampered by suboptimal surgery. There is controversial data about efficacy of this adjuvant therapy in patients who have undergone D2 lymphadenectomy predominantly. In our hospital D2 lymphadenectomy is standar surgery for gastric cancer. Methods: Retrospective study with gastric adenocarcinoma patients stage II to IV M0 who underwent curative resection at Instituto Nacional de enfermedades Neoplasicas Lima- Peru between 2001 and 2006 Standard treatment at institution is D2 lymphadenectomy. Chemoradiotherapy according to INT 0116 was given like adjuvant therapy. Survival curves were calculated according to Kaplan-Meier method and compared with log-rank test. Multivariate analysis of prognostic factors related to survival was performed by Cox proportional hazards model adjusted for age, stage and adjuvant chemoradiotherapy. Results: 84 patients were included 60.3% male and 39.3% female. Median age was 40.5 years old. The patologic stage were T1-T2 (12.3%), T3-T4 ( 50% ), N0-N1 (10.7%), N2-N3 (89.3%). D2 lymphadenectomy was performed in all patients. The 3-year DFS was 17% and 3-year overall survivall was 23.9% years.However when we analized by subgroups the overal survival was significantly longer in group N1 ( 61%) and N2 (58.9%) that N3 (18.3%) and DFS were N1 (60%), N2 (55%) and N3 (16.3%). Conclusions: Adjuvant chemoradiotherapy decreased risk of death and relapse in patients with node positive N1-N2 , who underwent curative resection with D2 lymphadenectomy, but recurrence was most frecuent in N3 node positive, maybe is necesary improve the chemotherapy in this group of patientes for dicrease the rate of relapse.


Cancer ◽  
1999 ◽  
Vol 85 (7) ◽  
pp. 1490-1499 ◽  
Author(s):  
Noe K. Kim ◽  
Hark K. Kim ◽  
Byung J. Park ◽  
Min S. Kim ◽  
Yong I. Kim ◽  
...  

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 152b-152b
Author(s):  
H. Hur ◽  
J. Y. Kim ◽  
Y. B. Kim ◽  
Y. A. Lim ◽  
Y. K. Cho ◽  
...  

152b Background: Although two prospective studies reported that negative H pylori is associated with good prognosis in Western countries, these results are not generally acceptable due to regional differences in H pylori virulence and incidence of gastric cancer. Here, we prospectively assessed the correlation between H pylori status of patients who underwent curative resection for treatment of gastric adenocarcinoma and their prognosis in Korea, where H pylori is highly prevalent in the population. Methods: Between 2006 and 2007, 192 patients who had undergone curative resection for treatment of gastric adenocarcinoma were prospectively enrolled. Of these patients, 18 patients were excluded due to inexact evaluation of H pylori status, and 174 patients were finally analyzed. Serologic testing for H pylori was assessed using an enzyme-linked immunosorbent assay kit for IgG, and histological presence was identified using Giemsa stain. Results: Of 174 patients, 111 patients (63.8%) who showed both serologically and histologically positive results were confirmed as having positive H pylori infection. H pylori status was not correlated with overall or disease-free survival. In term of patients who were diagnosed with AJCC stage III or IV, disease-free survival of patients with positive H pylori status was a significant predicting factor for recurrence longer than that of negative patients (p = 0.019). Negative H pylori status became a predicting factor for recurrence in multivariable analysis (RR = 2.724, 95% C.I.: 1.192-6.228). Conclusions: H pylori status did not show correlation with clinicopathologic factors of gastric adenocarcinoma in Korea. However, negative H pylori may be a predictive factor for recurrence in patients diagnosed with gastric adenocarcinoma of advanced status. Therefore, in H pylori endemic areas, patients diagnosed with locally advanced gastric cancer accompanied by negative H pylori status should be considered for an aggressive treatment strategy and close follow-up. In addition, correlation in an early stage should be confirmative through the results of longer follow-up. No significant financial relationships to disclose.


2011 ◽  
Vol 19 (5) ◽  
pp. 1560-1567 ◽  
Author(s):  
Hiromichi Miyagaki ◽  
Makoto Yamasaki ◽  
Tsuyoshi Takahashi ◽  
Yukinori Kurokawa ◽  
Hiroshi Miyata ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document